LSK Global Pharma Services (PS) said that it would conduct and support the International Vaccine Institute's (IVI) clinical trials of Inovio's INO-4800, a Covid-19 vaccine, in Korea.
Under an agreement, IVI, Seoul National University Hospital and SNU Bundang Hospital will lead the phase 1 and 2 clinical trials of INO-4800. LSK will be responsible for the trial's general clinical operations, including project management, monitoring, data management, and pharmacovigilance activities.
"We are pleased to begin this clinical trial following the selection of LSK Global PS and taking the next steps toward developing a Covid-19 vaccine, which has been eagerly awaited by people worldwide," IVI Director General Jerome Kim said. "We believe that the clinical trial will be conducted quickly and accurately by bringing together top experts from different fields."
LSK Global PS President Lee Young-Jack said, "We are honored to conduct the first approved clinical trial of a COVID-19 vaccine in Korea and play our role as a leading contract research organization (CRO) in addressing the growing expectations for a Covid-19 vaccine."
<© Korea Biomedical Review, All rights reserved.>